TATE-PD1
Phase 2 Recruiting
54 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Phase 2/3 Recruiting
840 enrolled
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
2,130 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Phase 1 Recruiting
154 enrolled
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Phase 1 Recruiting
70 enrolled
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Phase 1/2 Recruiting
250 enrolled
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Phase 2/3 Recruiting
690 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Recruiting
260 enrolled
ERADIC8
Phase 1/2 Recruiting
120 enrolled
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Phase 1/2 Recruiting
71 enrolled
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
Phase 1 Recruiting
70 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Phase 2 Recruiting
454 enrolled
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 2 Recruiting
163 enrolled
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Phase 2 Recruiting
172 enrolled
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
Phase 1 Recruiting
135 enrolled
Study for AZD4360 in Participants With Advanced Solid Tumours
Phase 1/2 Recruiting
117 enrolled
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
60 enrolled
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Phase 3 Recruiting
726 enrolled
FAPI-GO
Phase 3 Recruiting
200 enrolled
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Phase 1/2 Recruiting
980 enrolled
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Phase 2 Recruiting
100 enrolled
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
572 enrolled
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
330 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Phase 1 Recruiting
200 enrolled
Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder
Phase 2 Recruiting
87 enrolled
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/2 Recruiting
134 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Phase 3 Recruiting
550 enrolled
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
Phase 2 Recruiting
180 enrolled
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/2 Recruiting
147 enrolled
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
280 enrolled
DG-03
Phase 2 Recruiting
450 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled